About tempest therapeutics inc - TPST
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.
TPST At a Glance
Tempest Therapeutics, Inc.
2000 Sierra Point Parkway
Brisbane, California 94005
| Phone | 1-415-798-8589 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -26,262,000.00 | |
| Sector | Health Technology | Employees | 4 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
TPST Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.121 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.469 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.66 |
TPST Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -6,565,500.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
TPST Liquidity
| Current Ratio | 2.495 |
| Quick Ratio | 2.495 |
| Cash Ratio | 2.326 |
TPST Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -83.167 |
| Return on Equity | -203.629 |
| Return on Total Capital | -177.338 |
| Return on Invested Capital | -128.468 |
TPST Capital Structure
| Total Debt to Total Equity | 122.091 |
| Total Debt to Total Capital | 54.973 |
| Total Debt to Total Assets | 42.556 |
| Long-Term Debt to Equity | 104.214 |
| Long-Term Debt to Total Capital | 46.924 |